As of November 6, 2026, Radiopharm Theranostics Ltd is a publicly traded company (Nasdaq: RADX). The largest holder reporting an active stake on Schedule 13D is Lantheus Holdings, Inc., at 20.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Lantheus Omega, LLC (17.3%), Regal Partners Holdings Pty Limited (9.05%), Regal Funds Management Pty Limited (7.3%) (Schedule 13D, September 4, 2026).
Is this your company?
About to sign with, pay or invest in Radiopharm Theranostics Ltd? See the free Snapshot first.
Free to see. No signup.
Is Radiopharm Theranostics Ltd a real, registered company?
- Radiopharm Theranostics Limited files with the SEC under CIK 1949257 (its SEC filings).
- Its shares are listed under the ticker RADX on Nasdaq (also RDPTF) (SEC company record).
- Incorporated in C3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Radiopharm Theranostics Limited in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Lantheus Omega, LLC (filed 2026-09-04).
Who are Radiopharm Theranostics Ltd's owners and officers?
Radiopharm Theranostics Ltd: industry Pharmaceutical Preparations (Schedule 13G, 2026-10-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-14 | Regal Partners Funds Management Pty Limited | 3.34% |
| Schedule 13G, 2026-09-04 | Lantheus Omega, LLC | 17.3% |
| Schedule 13D, 2026-09-04 | Lantheus Holdings, Inc. | 20.9% |
| Schedule 13G/A, 2026-01-16 | Jpmorgan Chase & Co. | 4% |
| Schedule 13G, 2026-01-08 | Regal Partners Holdings Pty Limited | 9.05% |
| Schedule 13G, 2025-07-23 | Regal Funds Management Pty Limited | 7.3% |
| Schedule 13G/A, 2025-07-16 | Jpmorgan Chase & Co. | 9% |
Questions about who owns Radiopharm Theranostics Ltd
Who owns Radiopharm Theranostics Ltd?
On this page, 4 holders' latest ownership filings report 5% or more of Radiopharm Theranostics Ltd: Lantheus Holdings, Inc. (20.9%, Schedule 13D, filed 2026-09-04), Lantheus Omega, LLC (17.3%, Schedule 13G, filed 2026-09-04), Regal Partners Holdings Pty Limited (9.05%, Schedule 13G, filed 2026-01-08) and Regal Funds Management Pty Limited (7.3%, Schedule 13G, filed 2025-07-23).
Who are the largest shareholders of Radiopharm Theranostics Ltd?
By the share each holder's latest filing reports, the largest holders of Radiopharm Theranostics Ltd on this page are Lantheus Holdings, Inc. (20.9%), Lantheus Omega, LLC (17.3%) and Regal Partners Holdings Pty Limited (9.05%).
When did Lantheus Holdings, Inc. buy into Radiopharm Theranostics Ltd?
The filings give report dates, not purchase dates. The earliest filing from Lantheus Holdings, Inc. on this page is the Schedule 13D, filed 2026-09-04, reporting 20.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Radiopharm Theranostics Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Radiopharm Theranostics Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Radiopharm Theranostics Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Radiopharm Theranostics Ltd shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 147,721,428 shares (4.2% of shares outstanding), 53,900,000 held directly and 93,821,428 indirectly (Form 3, 2026-05-06).
- , the chief executive and a director: 22,679,986 shares (0.64% of shares outstanding) (Form 3, 2026-03-31).
- , a director: 9,985,292 shares (0.28% of shares outstanding), 6,985,292 held directly and 3,000,000 indirectly (Form 3, 2026-04-01).
- , a director: 644,247 shares (0.02% of shares outstanding) (Form 3, 2026-03-31).
- , the chief financial officer: 26,357 shares (0.00% of shares outstanding) (Form 3, 2026-04-30).
Shares outstanding: 3,544,216,160 as of 2026-06-30, from the company's latest SEC cover page.
How much has Radiopharm Theranostics Ltd raised?
Latest IPO step: Radiopharm Theranostics Ltd filed to go public (F-1, 2024-12-05).
IPO filings: F-1, 2024-12-05; ticker RADX on Nasdaq Capital Market.
Keep reading
More on Radiopharm Theranostics Ltd and the records around it.
Radiopharm Theranostics Ltd elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Lantheus Omega, LLC also filed stake reports on 1 other company: Perspective Therapeutics, Inc. (Sep 2026)
- Regal Partners Funds Management Pty Limited also filed stake reports on 1 other company: EBR Systems, Inc. (Jul 2026)
- JPMORGAN CHASE & CO. also filed stake reports on 116 other companies: LEVI STRAUSS & CO (Nov 2026), Warner Music Group Corp. (Nov 2026), Andersen Group Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/radiopharm-theranostics